---
title: "Ascentage Pharma presents Phase II China study on Lisaftoclax at ASH Annual Meeting, supporting NDA approval by NMPA in July 2025."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/268835326.md"
description: "Ascentage Pharma presented successful Phase II study results of Lisaftoclax at the ASH Annual Meeting, leading to its approval by China's NMPA in July 2025. The study focused on patients with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma who failed BTK inhibitors. Ascentage Pharma is listed on NASDAQ and HKEX, specializing in cancer therapies."
datetime: "2025-12-06T15:15:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/268835326.md)
  - [en](https://longbridge.com/en/news/268835326.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/268835326.md)
generator: "portal-rs"
---

# Ascentage Pharma presents Phase II China study on Lisaftoclax at ASH Annual Meeting, supporting NDA approval by NMPA in July 2025.

On December 6, 2025, Ascentage Pharma Group International Inc. disclosed at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, FL, that their Phase II study in China involving Lisaftoclax (APG-2575) for relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma patients who failed Bruton’s tyrosine kinase inhibitors (BTKis) was successful. The National Medical Products Administration (NMPA) of China approved Lisaftoclax in July 2025 following data from this critical trial. Ascentage Pharma Group, a biopharmaceutical company traded on NASDAQ (AAPG) and HKEX (6855), specializes in developing innovative therapies for cancer treatment.

### Related Stocks

- [AAPG.US](https://longbridge.com/en/quote/AAPG.US.md)
- [AAPGV.US](https://longbridge.com/en/quote/AAPGV.US.md)

## Related News & Research

- [Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates | AAPG Stock News](https://longbridge.com/en/news/296408912.md)
- [Ascentage Pharma posts interim results presentation on 1H 2026 business update](https://longbridge.com/en/news/296418315.md)
- [ASCENTAGE  Plans ATM Offering of ADSs in US to Raise Up to USD200 million](https://longbridge.com/en/news/293143188.md)
- [Ascentage Pharma corrects AGM date tied to RSU, option grant mandate to May 19, 2025](https://longbridge.com/en/news/292530336.md)
- [Ascentage Pharma Showcases Broad Leukemia Data for Olverembatinib and Lisaftoclax at EHA2026](https://longbridge.com/en/news/289705908.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**